TY - JOUR
TI - Topical estrogens and non-hormonal preparations for postmenopausal vulvovaginal atrophy: An EMAS clinical guide
AU - Hirschberg, A.L.
AU - Bitzer, J.
AU - Cano, A.
AU - Ceausu, I.
AU - Chedraui, P.
AU - Durmusoglu, F.
AU - Erkkola, R.
AU - Goulis, D.G.
AU - Kiesel, L.
AU - Lopes, P.
AU - Pines, A.
AU - van Trotsenburg, M.
AU - Lambrinoudaki, I.
AU - Rees, M.
JO - Maturitas
PY - 2021
VL - 148
TODO - null
SP - 55-61
PB - Elsevier Ireland Ltd
SN - 0378-5122
TODO - 10.1016/j.maturitas.2021.04.005
TODO - emollient agent;  estrogen;  lubricating agent;  estrogen, application site irritation;  Article;  breast cancer;  breast tenderness;  cancer adjuvant therapy;  cancer risk;  candidiasis;  cardiovascular disease;  cardiovascular risk;  consensus;  drug efficacy;  drug safety;  drug use;  endometrium cancer;  female;  female genital tract cancer;  hip fracture;  human;  information retrieval;  low drug dose;  Medline;  meta analysis (topic);  ovary cancer;  peritoneum cancer;  postmenopause;  publication;  randomized controlled trial (topic);  recurrent disease;  systematic review (topic);  topical treatment;  urinary tract infection;  urine incontinence;  uterine cervix cancer;  uterine tube tumor;  uterus sarcoma;  vagina atrophy;  vagina bleeding;  vagina cancer;  vagina discharge (disease);  vagina mycosis;  vaginitis;  venous thromboembolism;  atrophy;  expert witness;  intravaginal drug administration;  practice guideline;  quality of life;  vagina disease;  vulva disease, Administration, Intravaginal;  Atrophy;  Estrogens;  Expert Testimony;  Female;  Humans;  Postmenopause;  Practice Guidelines as Topic;  Quality of Life;  Vaginal Diseases;  Vulvar Diseases
TODO - Introduction: Vulvovaginal atrophy (VVA) is a chronic condition caused by estrogen deficiency. It affects around 50% of postmenopausal women, reducing their general and sexual quality of life as well as the quality of their personal relationships. Aim: The aim of this clinical guide is to set out an individualized approach to the management of VVA with topical estrogens and non-hormonal preparations. Materials and methods: Literature review and consensus of expert opinion. Summary recommendations: An individualized approach is required for the management of VVA. Topical low-dose estrogens are effective and also alleviate urinary incontinence and prevent recurrent urinary tract infections. Women should not be denied long-term use of topical estrogens as long as they feel that this treatment is of benefit to them, because the safety data are reassuring. Non-hormonal preparations (lubricants and moisturizers) should be the first-line treatment for VVA in women taking adjuvant endocrine therapies for cancers considered to be hormone-dependent. They can be used over the long term. © 2021
ER -